Talker Research polled 2,000 beauty-conscious adults for a cosmetics company. Most users said they got no warning about facial volume or muscle loss, yet 68% would still take the drug.
Recap by typeshit. Full story at StudyFinds.
He says close to 40% of weight lost in the trial's body-scan group was lean mass, and argues muscle loss isn't the drug's fault.
Wayne Pratt walks through what happens in the brain when drugs like Ozempic dial down the constant background chatter about eating.
Bikman cites a trial where people who lost about 21% and switched to placebo regained 14% within a year, while those who stayed on kept losing.
In Genome Medicine, diet-triggered delivery beat constant secretion on fat and liver fat, and kept down gut microbes carrying GLP-1-degrading peptidase genes.
Penn researchers in JAMA Network Open found new oral semaglutide starts briefly passed the injection in early March 2026. Tirzepatide stayed ahead the whole time.
Longo was asked if pulsing growth hormone peptides could raise IGF-1 the way exercise does instead of keeping it high. The clip is gated behind a comment-for-link prompt.
Loading…